Taro announces merger with Sun Pharma in ₹2,892 crore deal

Upon completion of the merger, currently expected to close in the first half of 2024, Taro will become a privately held company and its shares will no longer be listed on the NYSE.

January 18, 2024 11:48 am | Updated 12:17 pm IST - MUMBAI

Dilip Shanghvi, Managing Director, Sun Pharma. File photo

Dilip Shanghvi, Managing Director, Sun Pharma. File photo | Photo Credit: The Hindu

Sun Pharmaceutical Industries Ltd and Taro Pharmaceutical Industries Ltd have entered into a definitive merger agreement in which Sun Pharma, Taro’s controlling shareholder, would acquire all of the outstanding ordinary shares of Taro other than the shares already held by it (Sun Pharma) or its affiliates for US$43 per share in cash without interest.     

 The total cost of acquisition of 80,86,818 shares constituting 21.52% of the total outstanding shares of Taro amounts to US$ 347.73 million (₹2,892 crore), Sun Pharma said in a filing with stock exchanges. 

Dilip Shanghvi, Managing Director, Sun Pharma, in a statement said, “Over the years, with Sun Pharma’s strategic interventions, Taro has remained a key player in the generic dermatology market in a challenging environment. Post completion of the merger, the combined entity will firmly move forward, leveraging its global strengths and capabilities to better serve the needs of patients and healthcare professionals.”

Uday Baldota, Chief Executive Officer of Taro, said, “This merger will further enable us compete effectively in our products and markets.”

The US$43 per share purchase price represents a 48% premium over the closing price of US$28.97 per share on May 25, 2023, the last trading day before Sun Pharma first submitted its non-binding proposal to Taro, and a premium of 58% to the volume-weighted average price of the shares during the 60 days prior to and including May 25, 2023. 

The purchase price also represents a 13% increase over the initial proposed purchase price of US$38.00 per share as proposed on May 26, 2023, Sun Pharma said. 

The merger agreement was unanimously recommended by the Special Committee, which was formed by Taro’s Board of Directors to consider Sun Pharma’s proposal, it added.

The merger is subject to various closing conditions.

Upon completion of the merger, currently expected to close in the first half of 2024, Taro will become a privately held company and its shares will no longer be listed on the NYSE..

Top News Today

Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.